Patients with Type 2 diabetes [chronic renal dysfunction (CKD Stage:over G3b)]
Conditions
Interventions
Teneligliptin 20mg/day 1week
Sponsors
Kitano Hospital, The Tazuke Kofukai Medical Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients agreed to participate in this study with a written consent 2) Gender: agnostic 3) Age: 20 years old or older when obtaining consent 4) Inpatient and outpatient: hospitalization 5) Patients who continued diet and exercise therapy more than 12 weeks before day1. Exercise therapy is not essential if it is prohibited because of the complication. 6) CKD stage over G3b based on serum Cystatin C level within four weeks of day1.
Exclusion criteria
Exclusion criteria: 1)Type 1 diabetes,diabetes arising from the failure of pancreas,or secondary diabetes (eg. Cushing's syndrome and acromegaly) 2) Patient correspond to contraindications of teneligliptin 3) Excessive alcohol addicts: patient who take average net more than 60 g alcohol every single day (more than following: 3 bottles of sake, 1 with shochu, 3 bottles of beer, 3 glasses of whiskey or brandy(double),and 5 glasses of wine) 4) Pregnant, lactating, possible pregnant patient 5) Patient judged as ineligible for this study by the researcher
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentration of teneligliptin Changes in active GLP-1 levels | — |
Secondary
| Measure | Time frame |
|---|---|
| C-peptide- and glucagon-response to the meal test | — |
Countries
Japan
Outcome results
None listed